Questions about the new Sanofi #denguevaccine? In the latest - TopicsExpress



          

Questions about the new Sanofi #denguevaccine? In the latest Phase 3 trial, the vaccine showed 60% efficacy (on average) and 42% in dengue 2 strain among youth 9-16 in Latin America. Note that the previous Phase 3 trial in Asia demonstrated a much lower efficacy with dengue 2 (35% & not statistically significant) and also sampled a different population (ages 2-14). Read the DVI statement here: ow.ly/B9LHP In Latin America the majority of youth have already been exposed to dengue by age 9 - so we are curious to see efficacy in a dengue-naive youth population. The good news about the vaccine: one more tool (with mosquito control, community prevention, etc) in an integrated approach to preventing and controlling #dengue! Photo: SSI Nicaragua
Posted on: Fri, 05 Sep 2014 22:15:23 +0000

Trending Topics



Recently Viewed Topics




© 2015